Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Flumazenil

Criteria

Inclusion Criteria:

• Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg

• Clinically normal physical findings, medical history and laboratory values.

Exclusion Criteria:

• Clinically significant illness or clinical relevant trauma within 2 weeks before the study start.

• Intake of another investigational drug or participation in a clinical study the past 12 weeks.

• Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.